HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

LQFM212

Also Known As:

2,6-di-tert-butyl-4-((4-(2-hydroxyethyl)piperazin-1-yl)methyl)phenol

Networked: 2 relevant articles (1 outcomes, 0 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Piperazines: 26
    - LQFM212: 2

Experts

1.	Cardoso, Carina Sofia: 1 article (01/2021)
2.	Costa, Elson Alves: 1 article (01/2021)
3.	Florentino, Iziara Ferreira: 1 article (01/2021)
4.	Ghedini, Paulo César: 1 article (01/2021)
5.	Menegatti, Ricardo: 1 article (01/2021)
6.	Moreira, Lorrane Kelle da Silva: 1 article (01/2021)
7.	Siqueira, Lorrayne: 1 article (01/2021)
8.	da Silva, Daiany Priscilla Bueno: 1 article (01/2021)
9.	da Silva, Dayane Moreira: 1 article (01/2021)
10.	de Brito, Adriane Ferreira: 1 article (01/2021)

Related Diseases

1.	Neuroinflammatory Diseases 01/01/2023 - "LQFM212 presents antioxidant activity and ameliorates behavioral, inflammatory and oxidative changes after LPS-induced neuroinflammation model. " 01/01/2023 - "In LPS-induced neuroinflammation, LQFM212 treatment reverted changes caused by LPS, demonstrated by attenuated anxiogenic- and depressive-like behaviors, reduced pro-inflammatory cytokines (TNF-α and IL-1β) and increased anti-inflammatory cytokines (IL-4 and IL-10) on serum, and also improved oxidative stress-related changes (levels of nitrite, malondialdehyde, glutathione and carbonylated protein, and superoxide dismutase, catalase, myeloperoxidase and cholinesterase activities) on brain cortex and hippocampus. "
2.	Cognitive Dysfunction 01/01/2021 - "In this regard, we have previously shown that the piperazine derivative 2,6-di-tert-butyl-4-((4-(2-hydroxyethyl)piperazin-1-yl)methyl)phenol (LQFM212) has anxiolytic-like activity which involves serotonergic pathway, nicotinic receptors and BZD-site of GABAA receptor, without cognitive impairments. "
3.	Pleurisy (Pleuritis) 01/01/2023 - "These effects do not seem to be secondary to a peripheral anti-inflammatory action of LQFM212, since this compound failed to attenuate the inflammatory changes in LPS-induced pleurisy model." 01/01/2023 - "However, LQFM212 treatment did not attenuate the inflammatory changes in LPS-induced pleurisy model. "
4.	Inflammation (Inflammations) 01/01/2023 - "Afterwards, the effects of oral treatment with LQFM212 were evaluated in mice using LPS-induced models of systemic or local inflammation. "
5.	Body Weight (Weight, Body) 01/01/2021 - "In assessment of possible adverse effects, repeated treatment with LQFM212 did not alter the body weight of the animals, glutathione levels in the liver, and serum levels of AST, ALT, urea, and creatinine. "

Related Drugs and Biologics

1.	Glutathione (Reduced Glutathione)
2.	Cytokines
3.	Superoxide Dismutase
4.	Proteins (Proteins, Gene)
5.	Nitrites
6.	Peroxidase (Myeloperoxidase)
7.	Malondialdehyde (Propanedial)
8.	Cholinesterases (Cholinesterase)
9.	Catalase
10.	Antioxidants